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β-lactams, such as penicillin, are the most 
widely prescribed class of antibiotics.  
In response to their extensive use and 
misuse, bacteria have become resistant to 
a growing number of these drugs.  Many 
antibiotic-resistant bacteria express the 
enzyme β-lactamase, the most widespread 
resistance mechanism to β-lactams.  
These enzymes cleave the defining lactam 
ring, rendering the antibiotic inactive 
against its original cellular target, thereby 
allowing the bacteria to survive.  As a 
result, antibiotic resistance has become 
a critical concern to human health.  An 
example of an antibiotic resistant bacterial 
species that has shown pathogenic 
properties is Acinetobacter baumannii.  
A significant portion of the resistance of 
this organism is due to its expression of 
the β-lactamase, Acinetobacter-derived 
cephalosporinase-7 (ADC-7).  In order 
to combat the antibiotic resistance in 
Acinetobacter, molecules were designed 
that could potentially bind ADC-7 and 
inhibit its ability to break down antibiotics. 
However, to facilitate the characterization 
and optimization of inhibitor design, the 
molecular structure of ADC-7 needs to 
be determined.  In collaboration with 
Dr. Rachel Powers, we have recently 
determined the structure of ADC-7 with 
and without a bound inhibitory molecule.  
Currently, we are attempting to identify 
a specific molecule that can bind ADC-7 
with high affinity and sufficiently inhibit 
ADC-7 to be considered an effective drug.  
The goal of this study is to characterize 
a promising new inhibitory compound 
of ADC-7 (S06017) and determine 
the efficacy with which this drug can 
inactivate the β-lactamase enzyme.  In 
order to determine whether the inhibitor 
substantially decreases the enzyme activity, 
competition kinetics were performed with 
S06017 against a diagnostic substrate 
of ADC-7 (nitrocefin).  Competition 
kinetics assays yield a Ki value, which is 
a measurement of the ADC-7/inhibitor 
binding affinity, with lower Ki values 
indicating higher binding affinities.  While 
the resulting Ki of 6.108 µM demonstrates 
that S06017 does bind and inhibit 
ADC-7’s ability to break down nitrocefin, 
the ADC-7/S06017 binding affinity is 
weaker than other related compounds.  
For example, the inhibitory compound 
S02030 binds ADC-7 with a Ki of 0.0373 
µM, and competition kinetics performed 
with CR192 resulted in an average Ki 
of 0.00045 µM.  Even though S06017 
binds ADC-7 with lower affinity than 
related molecules, the question remains:  
what specific parts of these molecules are 
responsible for binding tightly to ADC-7?  
By determining the X-ray crystal structure 
of ADC-7 with S06017 bound in its active 
site, it is possible to compare the specific 
orientation and interactions involved 
in inhibitor binding.   In addition, by 
comparing the ADC-7 structures in a 
complex with different compounds, it 
is possible to optimize the molecular 
structure of compound that will serve 
as the most efficient inhibitor of ADC-
7.  Comparing all of the X-ray crystal 
structures, as well as the KI values from 
competition kinetics, will hopefully lead to 
the discovery of an inhibitory drug that will 
significantly inhibit ADC-7, which could 
aid in combatting antibiotic resistance in 
Acinetobacter baumannii.
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